Bulgaria is one of Europe’s most underrated clinical research markets.
With a population of 6.4 million, 790 ongoing trials, fast BDA approval targets and a clinical research sector valued at $330M, Bulgaria offers sponsors a rare mix of regulatory speed, patient access and cost efficiency.
The country is especially relevant for oncology, cardiovascular disease, neurology, endocrinology, diabetes, respiratory disease and late stage commercial enrollment.
For sponsors, Bulgaria is not only a lower cost EU geography. It is a mature trial market with strong patient retention, treatment naive populations, motivated investigators and full EU CTIS alignment.